#Sweden #Stockholm #Alport Syndrome #Calliditas Therapeutics #Setanaxib

Calliditas Therapeutics Presents Safety Findings for Setanaxib

Calliditas Therapeutics, an Asahi Kasei company, recently unveiled important safety data for their investigational drug, Setanaxib, during the American Society of Nephrology (ASN) Kidney Week held in Houston, Texas. The data shared relates specifically to a Phase 2a trial focusing on Alport syndrome, a rare genetic disorder that significantly impacts kidney function due to mutations in collagen type IV genes.

Overview of the Clinical Trial

The Phase 2a clinical trial enrolled 20 patients aged between 12 and 40 years who had been genetically confirmed to have Alport syndrome. The study design was randomized, double-blind, and placebo-controlled, aimed at understanding the safety and efficacy of Setanaxib over a 24-week period. In this trial, patients received either oral Setanaxib or a placebo alongside their standard background therapy. Notably, the primary endpoints included serious adverse events (SAEs) and adverse events of special interest (AESIs), while secondary endpoints focused on the changes in urine protein-creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR).

The trial showcased a well-structured methodology, with patients treated accordingly under strict safety guidelines. Thirteen participants were assigned to the Setanaxib group while seven received a placebo.

Safety and Efficacy Results

The results indicated that Setanaxib met its primary safety endpoints, showing comparable rates of adverse events between the two groups. Remarkably, there were no reported AESIs. Evaluating the efficacy of Setanaxib, the results were still promising; participants treated with the drug experienced a significant mean reduction in UPCR. Specifically, there was a 15% decrease at the 24-week mark and a substantial 27% reduction four weeks post-treatment compared to the placebo group. Moreover, two patients in the Setanaxib cohort achieved a significant ≥25% reduction in UPCR from baseline, a result not seen in the placebo group.

The trial also noted slight reductions in eGFR, with a mean decrease of 5% at 24 weeks compared to the baseline for the Setanaxib group. This indicates that while there was some impact on kidney function, the overall benefits of managing protein levels in the urine appear to carry considerable importance for the treatment.

Implications for Alport Syndrome Treatment

Professor Daniel Gale from Royal Free Hospital in London, who presented the findings, emphasized the significance of these results, highlighting that Setanaxib could represent an important new treatment option for patients suffering from Alport syndrome. Given the current lack of approved therapies for this patient group, the safety profile and preliminary efficacy data of Setanaxib lays a promising foundation for further exploration.

About Setanaxib

Setanaxib is recognized as a novel agent with unique properties aimed at reducing hydrogen peroxide levels and addressing inflammation and fibrosis—primary mechanisms implicated in the progression of Alport syndrome. This drug is currently being evaluated in ongoing clinical studies to better establish its benefits across broader patient populations.

Calliditas Therapeutics and Future Directions

Calliditas Therapeutics operates out of Stockholm, Sweden, focusing on the development of innovative treatments for severe diseases with unmet needs, like Alport syndrome. Their commitment to advancing healthcare solutions is evident through their continuous research and development endeavors. As they move forward, the company looks to expand its pipeline and explore the full therapeutic potential of Setanaxib.

In summary, the Phase 2a trial results presented at ASN Kidney Week mark a significant milestone in the journey toward enhancing treatment options for patients with Alport syndrome, potentially ushering in a new era of care for this previously underserved patient population.